<DOC>
	<DOCNO>NCT03038971</DOCNO>
	<brief_summary>A safety study conduct subject ≥16 year old evaluate safety 4 intralymphatic injection 2 different dose level investigational short tall ragweed product . Biomarkers assess baseline multiple time point post-treatment .</brief_summary>
	<brief_title>Study Evaluating Safety Ragweed Mix Given Intralymphatic Node Injections</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Phenol</mesh_term>
	<criteria>Between age 16 65 year old Seasonal Allergic Conjunctivitis ( without Allergic Rhinitis ) ragweed pollen Positive skin test reaction screen visit short ragweed extract Avoid disallow medication Females childbearing potential must pregnancy test must agree use acceptable method birth control Have blood urine analysis within normal limit Manifest positive reaction conjunctival allergen challenge ragweed pollen Have specific IgE ≥ 0.70 kU/L short ragweed Have ocular nasal condition could affect subject safety trial parameter Have presence active sinus , nasal , ocular infection Have allergy immunotherapy ragweed pollen Have compromise lung function ≤80 % predict</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>